In this regard, Infarnato et al. described higher potency of PF-06463922 across ALK variants in a panel of 10 NB cell lines, with IC50 values for inhibition of F1174L- and F1245C-mutated ALK significantly lower than those seen for its predecessor, crizotinib (0.2–10 nmol/L) [708]. This evidence concerns the gene ALK and neuroblastoma.